In the fall of 2012, Johnson and Johnson settled a small amount of lawsuits involving the Antipsychotic drug Risperdal. The Plaintiff’s in the Risperdal Lawsuit, all males, alleged that Risperdal cause them to develop male breasts.
A year later, Johnson and Johnson agreed to settle another lawsuit involving Risperdal. This time with the Department of Justice over improper marketing practices. Johnson & Johnson agreed to pay $2.2 billion in criminal and civil fines for promoting off-label use of Risperdal with vulnerable groups such as children and the elderly.
The Risperdal Lawsuits allege that Johnson and Johnson knew that children were susceptible to specific side effects from Risperdal such as an elevated production of the hormone prolactin. It is alleged that This increase in hormone production caused a number of young adolescent males to experience an increased breast tissue and develop a condition known as Gynecomastia.
Risperdal Lawyers have been filing Risperdal Gynecomastia lawsuits for years. Because the victims are minors, there is frequently an extended statute of limitations to file a Risperdal lawsuit. Risperdal Lawyers are hopeful that the recent $2.2billion settlement will mean that more settlements are likely for Risperdal Gynecomastia victims.